$DAKT

DAKTRONICS INC /SD/ (DAKT): Results of Operations and Financial Condition

DAKTRONICS INC /SD/ (DAKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dakt-20260502x8kexx991.htm EX-99.1 Document Exhibit 99.1 Daktronics Announces Fourth Quarter and Full Fiscal Year 2026 Results • Record net sales for fiscal 2026 of $838.7 million • Record orders for fiscal 2026 of $860.8 million • Q4 EPS of $0.17, adjusted EPS (1) of $

Original reporting
Published Jun 24, 2026, 11:43 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$DAKT
Bullish
medium confidence
Mentioned
$DAKT
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DAKTBullishMed
01

Why it matters

The most tradable elements are the combination of record revenue/orders, operating margin expansion, and a higher ending product backlog that sets up fiscal 2027 revenue visibility. However, the article also flags Q4 order softness and tariff-refund uncertainty, which can drive near-term sentiment swings.

02

Market read

A primary earnings release with multiple hard datapoints (revenue, EPS, margins, backlog) that can drive same-day positioning and near-term expectations for fiscal 2027.

03

What to watch

Tariff refunds are explicitly unrecognized due to eligibility/timing uncertainty; investors may reprice risk if future guidance quantifies exposure or if backlog composition shifts toward lower-margin programs.

Relevance 7/10Novelty 8/10Timing: post-market/filing day after-hours reaction to fiscal Q4 and full-year results

Background

The filing is Daktronics’ SEC 8-K (Item 2.02) reporting fiscal 2026 and Q4 results for the 53-week year ended May 2, 2026, alongside commentary tied to its three-year strategic plan.

Company-level read

Ticker impact

$DAKTBullishMedium confidence
Context

Daktronics reports fiscal 2026 results with record net sales/orders, Q4 adjusted EPS $0.27, and backlog $356.2M entering fiscal 2027.

Expected impact

Likely positive bias for the stock on earnings-quality and backlog visibility, with potential volatility if investors focus on the Q4 order decline and tariff-refund risk.

Evidence & confidence

The filing is a primary 8-K earnings release (Item 2.02) with multiple hard datapoints: record revenue/orders, operating margin expansion, and a multi-quarter backlog. Offsetting factors include Q4 orders down 7.7% and explicit monitoring of tariff refunds with no recognized amounts as of May 2, 2026.

Market effects

Signals demand resilience and pricing/operational execution in dynamic video display and control systems, potentially supporting sentiment for related industrial/AV infrastructure spend.

Limited direct regional read-through; primarily company-specific execution and backlog conversion.

Tariff-refund monitoring highlights policy-driven uncertainty that could affect broader industrial electronics/AV supply chains, but no quantified impact is provided.

Counterpoint

Despite record full-year metrics, the Q4 new orders decline (-7.7% YoY) could indicate deceleration risk that backlog conversion may not fully offset.

Key entities

  • Daktronics, Inc.

    Reports fiscal 2026 and Q4 results, including record net sales/orders, margin expansion, and ending product backlog of $356.2M.

  • Ramesh Jayaraman

    CEO quoted on execution against the three-year strategic plan and fiscal 2027 positioning.

  • Howard Atkins

    Acting CFO quoted on the year’s operating margin improvement and order drivers.

Related articles

$MURMedAI 8/10

Murphy Oil Sees Sharp Profit Increase

Murphy Oil Corp reported Q2 2026 adjusted net income of $225.8 million, nearly six times Q2 2025, as higher oil prices offset lower production and weaker gas. Adjusted EPS was $1.55 vs $1.51 consensus. Revenue rose to $926.3 million. Murphy kept its $0.35 dividend and raised 2026 capex midpoint to $1.55 billion.

$GSBDMed

Goldman Sachs BDC Q2 Earnings Call Highlights

Goldman Sachs BDC (NYSE:GSBD) reported no incentive fee in Q2, citing its three-year total-return lookback provision. NAV was $12.06/share at June 30 vs $12.17 in Q1. The board declared a Q3 base dividend of $0.32/share plus $0.03 supplemental. Investments were $3.2B fair value, non-accrual 2.9%, and net debt-to-equity 1.35x.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$GXOMed

GXO Logistics Q2 Earnings Call Highlights

GXO Logistics reported Q2 results and said it secured over $1 billion in expected incremental new-business revenue for 2026 and about $353 million for 2027. Management cited a $2.7 billion sales pipeline after quarter end. Operating cash flow was $76 million, free cash flow positive $12 million, cash $769 million, and net leverage 2.6x. GXO plans to target EBIT margins above 6% and deploy AI across ~50 sites in 2026.

$GRNDMed

Grindr Q2 Earnings Call Highlights

Grindr (NYSE:GRND) said free users remain central to its strategy, while AI tools are boosting engineering productivity. Management estimated engineering output rose about 2.5x from July 2025 to April 2026 with similar headcount, supporting a 39% to 42% adjusted EBITDA margin outlook. EDGE AI premium tier rollout is planned for later in fall; operating expenses ex cost of revenue were $71M vs $53M.

$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.